Cummings Keith Lamont — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Cummings Keith Lamont has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $31K.

Profile

Keith Lamont Cummings is the Chief Financial Officer of Pliant Therapeutics, Inc. (PLRX), a clinical-stage biopharmaceutical company focused on therapies for fibrosis. The most recent SEC filing dated January 23, 2026 (CIK 0001809204) lists him in the CFO role with no reported stock purchases or sales in that filing.

Board memberships

• Pliant Therapeutics, Inc.

Awards & honors

• Listed as CFO in SEC filing for Pliant Therapeutics, Inc. (PLRX) with no reported purchases or sales in the filing
• Contributes to financial governance and disclosure practices as part of the executive leadership team

Recent Transactions

Companies — Last 90 Days

• PLIANT THERAPEUTICS, INC. (PLRX) — 1 filings, last 2026-04-17

Frequently Asked Questions

Who is Cummings Keith Lamont?

Keith Lamont Cummings is the Chief Financial Officer of Pliant Therapeutics, Inc. (PLRX), a clinical-stage biopharmaceutical company focused on therapies for fibrosis. The most recent SEC filing dated January 23, 2026 (CIK 0001809204) lists him in the CFO role with no reported stock purchases or sales in that filing.…

How many SEC Form 4 filings has Cummings Keith Lamont submitted recently?

1 primary Form 4 filings in the last 90 days, covering 1 company.

Has Cummings Keith Lamont been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 1 open-market sales ($31K) across all tracked filings.

Where can I see all of Cummings Keith Lamont's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

• What is SEC Form 4?
• How to read insider buying signals
• Understanding Rule 10b5-1 trading plans
• Browse all insiders
• Most active insiders this week